Lignocaine metabolism in man
dc.contributor.author
Adjepon-Yamoah, Kenneth K.
en
dc.date.accessioned
2017-10-27T12:01:08Z
dc.date.available
2017-10-27T12:01:08Z
dc.date.issued
1974
dc.description.abstract
en
dc.description.abstract
A gas-liquid chromatographic (GLC) method has "been developed for the simultaneous assay of lignocaine and its two active metabolites, ethylglycylxylidide (EGX) and glycylxylidide (GX), using a
nitrogen-sensitive flame ionisation detector and single column temperature programming. A GLC method has also been developed for the assay of 4-hydroxyxylidine} a major metabolite of lignocaine.
Lignocaine metabolism was studied in healthy volunteers
following oral and intramuscular administration. The metabolism of
the drug was also studied in hospital patients (a) undergoing anaesthesia and a variety of gynaecological surgical procedures, (b) with chronic liver disease and (c) with acute myocardial infarction and/or
cardiac failure. The plasma antipyrine half-life "was measured in some
of these patients as an independent measure of hepatic drug metabolising activity.
In healthy volunteers lignocaine is extensively and rapidly
metabolised to EGX, GX and 4-hydroxyxylidine. 2,6 xylidine and
4-hydroxy lignocaine and other unidentified metabolites were also
present in the urine after lignocaine administration.
The absorption of lignocaine was delayed in laparoscopy
patients. The elimination of the drug from plasma was slow in patients
undergoing anaesthesia and other minor gynaecological procedures. The
elimination of antipyrine was not markedly altered by anaesthesia and/or surgery.
Lignocaine absorption, metabolism and elimination were
abnormal in four patients with chronic liver disease and the plasma
antipyrine half-life was abnormally prolonged in two.
During a constant intravenous infusion of lignocaine in
patients with acute myocardial infarction or cardiac failure no
'steady state' plasma concentrations of the drug were reached and
the concentrations rose progressively. The concentrations of lignocaine
were high and potentially toxic levels were reached in the
presence of cardiac failure and cardiogenic shock. There was a slow
cumulation of EGX and GX in plasma during prolonged lignocaine
infusion. The metabolism of lignocaine was impaired especially in
patients with cardiac failure or cardiogenic shock. Antipyrine
metabolism was abnormal in the patients with acute cardiac failure.
en
dc.identifier.uri
http://hdl.handle.net/1842/25365
dc.publisher
The University of Edinburgh
en
dc.relation.ispartof
Annexe Thesis Digitisation Project 2017 Block 14
en
dc.relation.isreferencedby
en
dc.title
Lignocaine metabolism in man
en
dc.type
Thesis or Dissertation
en
dc.type.qualificationlevel
Doctoral
en
dc.type.qualificationname
PhD Doctor of Philosophy
en
Files
Original bundle
1 - 1 of 1
- Name:
- Adjepon-YamoahKK_1974redux.pdf
- Size:
- 29.22 MB
- Format:
- Adobe Portable Document Format
This item appears in the following Collection(s)

